• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Tweardy Samuel David claimed ownership of 946,974 shares (SEC Form 3)

    5/2/25 4:25:44 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVRD alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Tweardy Samuel David

    (Last) (First) (Middle)
    535 HAROLD AVENUE NE

    (Street)
    ATLANTA GA 30307

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/15/2025
    3. Issuer Name and Ticker or Trading Symbol
    Tvardi Therapeutics, Inc. [ TVRD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 315,658 I By Trust(1)
    Common Stock 315,658 I By Trust(1)
    Common Stock 315,658 I By Trust(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Securities are directly held by a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
    /s/ Samuel D. Tweardy 05/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TVRD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TVRD

    DatePrice TargetRatingAnalyst
    7/14/2025$62.00Outperform
    Raymond James
    7/11/2025$52.00Overweight
    Cantor Fitzgerald
    6/12/2025$78.00Overweight
    Piper Sandler
    5/21/2025$65.00Outperform
    Oppenheimer
    5/15/2025$55.00Buy
    BTIG Research
    More analyst ratings

    $TVRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Tvardi Therapeutics with a new price target

      Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00

      7/14/25 8:56:16 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Tvardi Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00

      7/11/25 8:16:19 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Tvardi Therapeutics with a new price target

      Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00

      6/12/25 7:57:03 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

      Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo

      7/15/25 8:00:00 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

      Topline data from the REVERT IPF trial anticipated in 4Q 2025 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3.

      5/27/25 8:00:00 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tvardi Therapeutics to Participate in Upcoming Investor Conferences

      Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, NY. Details are as follows: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways Format: Fireside Chat Date: Tuesday, May 27, 2025 Time: 11:30 AM ET Jefferies Global Healthcare Conference Format: Corporate P

      5/20/25 8:00:00 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVRD
    SEC Filings

    See more
    • Tvardi Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      7/14/25 5:00:46 PM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tvardi Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      6/9/25 6:05:53 AM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Tvardi Therapeutics Inc.

      S-1 - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      5/30/25 4:03:26 PM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hall Wallace L Jr was granted 246,756 shares (SEC Form 4)

      4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      5/2/25 6:19:16 PM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Wirk Shaheen was granted 439,194 shares (SEC Form 4)

      4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      5/2/25 6:12:20 PM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Tweardy Samuel David claimed ownership of 946,974 shares (SEC Form 3)

      3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      5/2/25 4:25:44 PM ET
      $TVRD
      Biotechnology: Pharmaceutical Preparations
      Health Care